SSc-ILD

News

MSD records one hit, one miss with TL1A drug tulisokibart

MSD's tulisokibart was effective in a phase 2 trial in skin disorder hidradenitis suppurativa, but has failed a study in rare lung disorder SSc-ILD.

News

Boehringer files for new rare disease use for nintedanib in ...

Boehringer Ingelheim has filed for a new use for its lung drug nintedanib in the US and Europe, bidding to add the rare disease systemic sclerosis to the existing indication for idiopathic

News

ESC26: Isomab safety evidence on blood vessel growth for CAD

Isomab has presented landmark safety data at ESC, clearing the path for next-generation therapies to promote blood vessel growth in CAD.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Editor's Picks